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Summary.-Immune complexes of 125I-HSA-rat anti-HSA formed in vivo under
conditions of antibody excess were rapidly cleared from the circulation of both
normal and leukaemic Hooded rats. In HSA-immune rats most of the 125I-HSA
present in the blood was found to be cell-bound, but a proportion was present as
circulating immune complexes that could be precipitated from plasma by 2.50/o
polyethylene glycol. There was no evidence that clearance of a soluble antigen was
impaired in leukaemic animals.
THE CLEARANCE of antigen from the
circulation of an animal with specific anti-
body to that antigen (Dixon & Talmage,
1951) is dependent on a number offactors,
perhaps the most important being the
ratio of antigen to antibody in circulation
(Weigle, 1958). Most of the immune com-
plexes formed in circulation that are
of a size greater than 1IS ( >Ag2Ab2) are
rapidly cleared bythe mononuclear phago-
cyte system. in particular by the Kupffer
cells of the liver (Benacerraf et al., 1959;
Arend & Mannik, 1971). Smaller immune
complexes, formed in antigen excess, have
been found to remain longer in circulation,
and some formed with low-mol.-wt anti-
gens or haptens were found to circulate for
considerable periods (Schmidt et al., 1974).
The reticuloendothelial system can be
saturated by large quantities ofcirculating
soluble immune complexes (Haakenstad
& Mannik, 1974). Immune complexes con-
taining tumour antigen have been found
in the sera of tumour-bearing animals
(Thomson et al., 1973) and the presence
of such complexes has been adduced from
the finding that tumour-bearer sera can
abrogate lymphocyte cytotoxicity (Sjogren
et al., 1971; Baldwin et al., 1972). These
observations have led to the concept that
impairment of the immune clearance sys-
tem in animals bearing tumours may be
responsible for the continued presence of
circulating immune complexes.
To investigate the immune clearance
system in normal and tumour-bearing
animals we have followed the disappear-
ance from circulation of complexes formed
in vivo between radiolabelled human
serum albumin (HSA) and specific anti-
body. We have monitored the clearance of
the immune complexes from circulation,
both as the disappearance oflabelled anti-
gen and as the decrease in radioactivity
that was precipitable from plasma by
2.5% polyethylene glycol.
MATERIALS AND METHODS
Immunization procedure
Eight adult Lister Hooded/Cbi rats each
weighing 300 g were immunized with 200
jig alum-precipitated human serum albumin
(HSA) (AB Kabi, Stockholm, Sweden) per
rat in 2 separate sites and on 2 occasions
separated by an interval of 3 weeks.
In vivo clearance of 125I-HSA
Normal animals-.Two weeks after the
second immunization, the rats were anaes-
thetized with ether and 360 )ug radiolabelled
HSA in 0 4 ml isotonic saline was injected via
the sublingual vein. Blood samples of about
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0X2 g were taken from the tail into weighed
tubes containing 01 ml of 0'2M EDTA (pH
7.5) and the total radioactivity was assayed
in a Packard Auto-gamma spectrometer. An
additional blood sample w%as taken to deter-
mine the haematocrit value. From these data
the radioactivity per gram of blood was
calculated, and the rate of clearance deter-
mined using the equation:
injected 1251-HSA in circulation=
Cb X< Vb
x 100 ci
Where at timne t: Cb is the ct/min 1251/g blood,
Vb is the animal's blood volume in ml
(estimated as 7°ON ofthe body wt) and Ci is the
ct/min 1251-HSA injected at zero time.
The blood sample was centrifuged and the
radioactivity in 01 ml of the plasma-EDTA
supernatant was determined. The rate of
plasma clearance was calculated from the
equation:
00 injected 1251-HSA in plasma=
(Wb xH1+01) x Cp xVb 100 Wb X( Ci
Where at time t: Wb is the weight of the
blood sample, H is the haematocrit value,
and Cp is the ct/min 1251/ml plasma-EDTA.
(Vb and Ci as above.)
To each 0Iml sample of plasma-EDTA
was added 10 ml of a solution containing
2.5% (w/v) polyethylene glycol 6000 (PEG,
British Drug Houses Ltd, Poole, Dorset) and
0-075M NaCl in 0 li'i borate buffer (pH 8.3)
(Zubler et al., 1976). After 2 h at 0°C the
tubes were centrifuged at 1500 g for 45 min
in an MSE Mistral 6L centrifuge at 4TC. The
supernatants were discarded and the radio-
activity remaining in the tubes determined.
The results were expressed as:
(1) Qo plasma 1251-HSA that was precipit-
able by PEG;
(2) 00 injected 1251 that was precipitalle by
PEG.
Tumour-bearing animals. The clearance
of 125I-HSA from 4 normal and 4 immune
rats was examined 10 days after these animals
had been injected i.v. with 2 x 104 cells of the
Hooded rat leukaemia (HRL; Wrathmell,
1976). The passage number and cell concen-
tration used caused death of the rats within
14 days, though they remained ostensibly
well until 48 h before death. The experi-
39
mental protocol was the same as that
described for the non-tumour-bearing rats.
Labelling of human serum? albumin with
125Iodine
HSA (AB Kabi, Stockholm, Sweden) was
labelled with 125Jodine by the chloramine T
mnethod (McConahey & Dixon, 1966) to sp.
act. 0 8-1 0 tCi/jug. Before use, the 1251-
HSA wNas diluted 10-fold with unlabelled
HSA to give a total input of 360 jg/rat.
Esti,mation ofplasma levels of rat anti-HSA
These were determined by passive haem-
agglutination, using HSA coupled to sheep
red blood cells as the antigen source.
RESULTS
The clearance of 1251-HSA from the
circulation of normal and immunized
Hooded rats was followed for 6 h and the
results are shown in the Figure. 1251-HSA
was rapidly cleared from the circulation
ofimmune rats, whereas in control animals
the level of radioactivitv in the blood
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FiG. Clearance of 1251-HSA from the
circulation of normal (40, 0) or leukaemic
(,A A) Hooded rats that had been pre-
immunized with HSA (open symbols) or
were non-immune (closed symbols).
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TABLE I.-Clearance of 125I-HSA from the circulation of HSA-immune and non-immune
Hooded rats
0/ injected 125I*
In circulation
Time r
(min)
10
20
30
60
90
120
240
360
Control
89-3 + 1-4
86-6 + 5-3
83-5 + 8-3
77-2 + 6-8
75-5 + 6-6
69-5 + 3-6
57-8 + 5-4
49-6 + 2-7
Immune
30-0+ 12-8
10-8+4-8
5-7+1-6
7-4+ 1.0
7-1+1-0
8-4+ 1-8
8-2+0-7
8-1+0-8
In plasma
Control Immune
89-3+1-4 4-6+2-0
86-0+6-1 4-5+ 1-9
83-5+ 8-3 3-4+ 1.0
73-7+1-9 30+04
68-6+5-0 3 4+0 7
66-2+2-9 4-2+1-1
49-2+3-7 4-1+05
42-9+3-1 40+0i4
Precipitable from plasma
by 2-5% PEG
Control Immune
1-1+0-23 30+1-77
1-1+0-10 3-0+1-45
0 7+0 04 1-5+0-71
0 7+004 04+0-08
0-7+009 03+005
0 7+0 09 0-2+0-04
0 7+0 05 0-2+0-03
0 5+0 05 0-2+0-07
* Results are the means + s.d. for 4 HSA-immune or 4 control animals.
TABLE II.-Clearance of 125I-HSAfrom the circulation ofHSA-immune and non-immune
HRL tumour-bearing rats.
% injected 1251*
In circulation
Immune Control
26-6+ 18-0 89-8 + 7-4
14-5+11-5 95 0+ 1-7
122+9 9 89-3+2-5
11-4 +4-6 84-7 + 4-8
10-1 +3-4 73-6+3-1
10 0+ 2-9 75-6 + 7-3
93+2-9 61-9+2-1
8-0+2-7 56-2+7-9
In plasma-
Immune
17-0+ 23-8
11-5+ 14-0
10-0+ 119
6-1+ 3-6
5-0+1-3
4-8+ 0-8
4-8+0-2
4 0+ 0 4
--.-_-
Precipitable from plasma
by 2-5% PEG
Control Immune
0-8+0-21 4-2+3-65
0 9+0-29 2-6+1-52
0-9+0-20 1-3+0-53
0-8+0-17 0 3+0 07
0-7+0-22 0-3+0-22
0-8+0-21 0-2+0-12
0-5+0-11 0-1+0-03
0-6+033 01+0-02
* Results are the means + s.d. for 4 HSA-immune or 4 control animals.
decreased slowly and exponentially so that
6 h after injection about half the in-
jected dose remained in circulation. Dur-
ing this time, virtually all the circulating
125I-HSA in the controls was present in
the plasma fraction of the blood samples
(Table I). In the immune rats, where at
10 min 30% of the 1251-HSA remained in
circulation, only 4.6% of the input was
found in the plasma fraction, leaving
25.4% associated with the blood cells.
These results show that soluble complexes
of 1251-HSA-rat anti-HSA formed i.v.
were rapidly taken up by the cellular com-
ponents of the blood and cleared from
circulation.
Samples of plasma were assayed at
intervals for the presence of 1251-HSA-rat
anti-HSA complexes that were precipit-
able by PEG at a final concentration of
2.5% (Tables I and III). PEG-precipitable
TABLE III-% of 125Iodine remaining in
the plasma of normal or leukaemic rats
that was precipitable by 2.5% PEG
Non-tumour-
bearing*
Time
(min)
10
20
30
66
90
120
240
360
Control
1-2 _ 0-2
1-2+0-3
0-8 _ 0-2
09+0.1
1-0+0-3
1-4+ 01
1-0_+0-2
HSA-
immune
57-4 + 19-2
65-1+5-2
45-5+7-1
13-6+ 2-7
8-0 + 3-4
5-7+2-1
4-1+_1.5
Tumour-
bearing*
HSA-
Control immune
0 9+0-2 48-9+25-7
0 9+0 3 39-3+20-7
1 0+0 3 24-3+14-5
0 9+0-2 6-4+3-4
1-0+0-2 6-7_4-5
1-0+ 0-2 4-3 + 1 0
0-8+0-2 1-4+0-5
1 0±04 1.1+0.5
* Results are the means + s.d. for 4 HSA-immune
or 4 control animals.
soluble immune complexes were cleared
from circulation within 1 h though some
PEG-precipitable material could be de-
tected in the plasma of immune rats
throughout the experiment (Table III).
Time
(min)
10
20
30
60
90
120
240
360
Control
907+ 6-0
95-8 + 6-0
903_3-8
85-2+4-4
75 7 + 5 7
75 7 7-4
62-9 + 3-3
59-2+8-7
0"'64
C
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To discover whether tumour-bearing
animals retained their ability to clear
soluble immune complexes from circula-
tion, the experiment was repeated using
HSA-immune and control rats that had
been given 2 x 104 HRL cells i.v. 10 days
before (see Methods). This Hooded rat
leukaemia is a thy 1.1-bearing leukaemia
(Wrathmell, 1976) without Fc receptors.
The results presented in the Figure and
Table II show that the clearance of 1251-
HSA from the circulation in both immune
and control tumour-bearing rats was not
significantly different from that of non-
tumour-bearing animals. Again, 1251-HSA
complexes could be detected in the plasma
of tumour-bearing immune rats by pre-
cipitation with 2.5% PEG (Table III). In
one of the HSA-immune tumour-bearing
animals, about 8% of the input of 1251-
HSA was found to be precipitable by PEG
from plasma taken at 10 min but in this
animal no cell-bound radioactivity was
detected then or subsequently. In the
other tumour-bearing immune animals,
however, more than 700o of the 1251-HSA
in circullation at 10 min was cell-bound.
The haemagglutination titres of anti-
LSA in all sera taken at the start of each
experiment lay between 1/3200 to 1/6400
in the immune rats, whilst control rats
wTere negative.
DISCUSSION
After a single i.v. infusion of 125I-HSA,
the immune complexes formed in vivo by
HSA-immune rats were cleared rapidly
from circulation. We have shown that a
proportion of these complexes were sol-
uble and could be detected in vitro by
precipitation from plasma with PEG.
H-owever, the bulk of the radiolabelled
antigen in the circulation of immune rats
was bound to blood cells during the
initial phase of immune clearance. In the
control animals 125I-1HSA was cleared
more slowly, all of the radioactivity being
in the plasma fraction and none pre-
cipitable by PEG.
The reticuloendothelial system can be
saturated by injecting immune complexes
in slight antibody excess into normal mice
(Haakenstad & Mannik, 1974). To avoid
this complication an antigen dosage was
used that did not saturate the system and
did allow normal clearance. Under these
conditions HSA-immune, leukaemia-bear-
ing Hooded rats given the same quantity
ofantigen as control HSA-immune animals
were capable of cleariing the immune com-
plexes formed, and there was no significant
difference in either the rate or extent of
clearance. Again, a large proportion of the
1251-HSA remaining in the circulation of
immune animals was found to be bound to
blood cells. The Hooded rat leukaemia
does not bear Fc receptors so that it is
unlikely that HRL cells in the peripheral
blood assisted in the clearance of immune
complexes. We conclude that the presence
of the rat leukaemia did not affect the
normal mechanism for clearance of the
HSA-immune complexes.
The finding that most of the HSA-
immune complexes in circulation were
cell-bound leads us to question the validity
of some methods currently used for
monitoring immune complexes in vivo,
which rely on the use of serum or plasma
alone. Experiments are in progress to
determine the peripheral blood cells in-
volved in the clearance of immune
complexes.
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